Tags

Type your tag names separated by a space and hit enter

Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans.
J Clin Endocrinol Metab 2010; 95(6):3028-38JC

Abstract

CONTEXT

Heterozygous GNAS inactivating mutations are known to induce pseudohypoparathyroidism type 1a when maternally inherited and pseudopseudohypoparathyroidism when paternally inherited. Progressive osseous heteroplasia (POH) is a rare disease of ectopic bone formation, and studies in different families have shown that POH is also caused by paternally inherited GNAS mutations.

OBJECTIVE

Our purpose was to characterize parental origin of the mutated allele in de novo cases of POH and to draw phenotype/genotype correlations according to maternal or paternal transmission of a same GNAS mutation.

DESIGN AND SETTING

We conducted a retrospective study on patients addressed to our referral center for the rare diseases of calcium and phosphorus metabolism.

PATIENTS AND METHODS

We matched 10 cases of POH with cases of pseudohypoparathyroidism type 1a carrying the same GNAS mutations.

MAIN OUTCOME MEASURES

The parental origin of the mutated allele was studied using informative intragenic polymorphisms and subcloning of PCR products.

RESULTS

Paternal origin of GNAS mutations was clearly demonstrated in eight POH cases including one patient with mutation in exon 1. Genotype/phenotype analyses suggest that there is no direct correlation between the ossifying process and the position of the inactivating GNAS mutation. It is, however, more severe in patients in whom origin of the mutation is paternal. Severe intrauterine growth retardation was clearly evidenced in paternally inherited mutations.

CONCLUSIONS

Clinical heterogeneity makes genetic counseling a delicate matter, especially in which paternal inheritance is concerned because it can lead to either a mild expression of pseudopseudohypoparathyroidism or a severe expression of POH.

Authors+Show Affiliations

Department of Genetics and Reproduction, University Hospital-Caen, 14033 Caen, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20427508

Citation

Lebrun, M, et al. "Progressive Osseous Heteroplasia: a Model for the Imprinting Effects of GNAS Inactivating Mutations in Humans." The Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, 2010, pp. 3028-38.
Lebrun M, Richard N, Abeguilé G, et al. Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. J Clin Endocrinol Metab. 2010;95(6):3028-38.
Lebrun, M., Richard, N., Abeguilé, G., David, A., Coëslier Dieux, A., Journel, H., ... Kottler, M. L. (2010). Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. The Journal of Clinical Endocrinology and Metabolism, 95(6), pp. 3028-38. doi:10.1210/jc.2009-1451.
Lebrun M, et al. Progressive Osseous Heteroplasia: a Model for the Imprinting Effects of GNAS Inactivating Mutations in Humans. J Clin Endocrinol Metab. 2010;95(6):3028-38. PubMed PMID: 20427508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. AU - Lebrun,M, AU - Richard,N, AU - Abeguilé,G, AU - David,A, AU - Coëslier Dieux,A, AU - Journel,H, AU - Lacombe,D, AU - Pinto,G, AU - Odent,S, AU - Salles,J P, AU - Taieb,A, AU - Gandon-Laloum,S, AU - Kottler,M L, Y1 - 2010/04/28/ PY - 2010/4/30/entrez PY - 2010/4/30/pubmed PY - 2010/7/2/medline SP - 3028 EP - 38 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 95 IS - 6 N2 - CONTEXT: Heterozygous GNAS inactivating mutations are known to induce pseudohypoparathyroidism type 1a when maternally inherited and pseudopseudohypoparathyroidism when paternally inherited. Progressive osseous heteroplasia (POH) is a rare disease of ectopic bone formation, and studies in different families have shown that POH is also caused by paternally inherited GNAS mutations. OBJECTIVE: Our purpose was to characterize parental origin of the mutated allele in de novo cases of POH and to draw phenotype/genotype correlations according to maternal or paternal transmission of a same GNAS mutation. DESIGN AND SETTING: We conducted a retrospective study on patients addressed to our referral center for the rare diseases of calcium and phosphorus metabolism. PATIENTS AND METHODS: We matched 10 cases of POH with cases of pseudohypoparathyroidism type 1a carrying the same GNAS mutations. MAIN OUTCOME MEASURES: The parental origin of the mutated allele was studied using informative intragenic polymorphisms and subcloning of PCR products. RESULTS: Paternal origin of GNAS mutations was clearly demonstrated in eight POH cases including one patient with mutation in exon 1. Genotype/phenotype analyses suggest that there is no direct correlation between the ossifying process and the position of the inactivating GNAS mutation. It is, however, more severe in patients in whom origin of the mutation is paternal. Severe intrauterine growth retardation was clearly evidenced in paternally inherited mutations. CONCLUSIONS: Clinical heterogeneity makes genetic counseling a delicate matter, especially in which paternal inheritance is concerned because it can lead to either a mild expression of pseudopseudohypoparathyroidism or a severe expression of POH. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/20427508/Progressive_osseous_heteroplasia:_a_model_for_the_imprinting_effects_of_GNAS_inactivating_mutations_in_humans_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2009-1451 DB - PRIME DP - Unbound Medicine ER -